These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30078050)

  • 1. Hepatocyte-specific contrast media: not so simple.
    Trout AT; Towbin AJ; Smith EA; Gupta A; Dillman JR
    Pediatr Radiol; 2018 Aug; 48(9):1245-1255. PubMed ID: 30078050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
    Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
    Burke C; Alexander Grant L; Goh V; Griffin N
    Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical use and pitfalls of hepatocyte-specific contrast agents (HSCAs) for pediatric hepatic and biliary magnetic resonance imaging.
    Ayyala RS; Anupindi SA; Callahan MJ
    Abdom Radiol (NY); 2017 Feb; 42(2):502-520. PubMed ID: 27680015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic resonance imaging: What are the tips when using hepatocyte-specific agents?
    Park YS; Lee CH; Kim JW; Shin S; Park CM
    World J Gastroenterol; 2016 Jan; 22(1):284-99. PubMed ID: 26755877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging.
    Kim MJ; Rhee HJ; Jeong HT
    AJR Am J Roentgenol; 2012 Nov; 199(5):W575-86. PubMed ID: 23096201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
    Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
    Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging features of common focal liver lesions in children.
    Masand PM
    Pediatr Radiol; 2018 Aug; 48(9):1234-1244. PubMed ID: 30078045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte-specific magnetic resonance imaging contrast agents.
    Fidler J; Hough D
    Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous gadolinium-based hepatocyte-specific contrast agents (HSCAs) for contrast-enhanced liver magnetic resonance imaging in pediatric patients: what the radiologist should know.
    Ayyala RS; Anupindi SA; Gee MS; Trout AT; Callahan MJ
    Pediatr Radiol; 2019 Sep; 49(10):1256-1268. PubMed ID: 31350632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of gadoxetate biliary transit time in determining hepatocyte function.
    Wu J; Li H; Lin Y; Chen Z; Zhong Q; Gao H; Fu L; Sandrasegaran K
    Abdom Imaging; 2015 Jan; 40(1):95-101. PubMed ID: 25056714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver MR Imaging in Children: Current Concepts and Technique.
    Chavhan GB; Shelmerdine S; Jhaveri K; Babyn PS
    Radiographics; 2016; 36(5):1517-32. PubMed ID: 27618326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background.
    Yoneda N; Matsui O; Kitao A; Kozaka K; Kobayashi S; Sasaki M; Yoshida K; Inoue D; Minami T; Gabata T
    Radiographics; 2016; 36(7):2010-2027. PubMed ID: 27740898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
    Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
    AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primovist, Eovist: what to expect?
    Van Beers BE; Pastor CM; Hussain HK
    J Hepatol; 2012 Aug; 57(2):421-9. PubMed ID: 22504332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.
    Choi SH; Byun JH; Lim YS; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2016 May; 64(5):1099-1107. PubMed ID: 26820629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on clinical applications of hepatospecific contrast media in magnetic resonance imaging of liver parenchyma.
    Giuga M; De Gaetano AM; Guerra A; Infante A; Iezzi R; Spinelli I; Siciliano M; Grieco A; Rapaccini GL; Gasbarrini A; Pompili M; Bonomo L
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2515-25. PubMed ID: 27383300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast agents for MR imaging of the liver.
    Semelka RC; Helmberger TK
    Radiology; 2001 Jan; 218(1):27-38. PubMed ID: 11152776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.